XNCR Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals has a net margin of -147.92% compared to Xencor's net margin of 40.12%. Xencor's return on equity of -32.34% beat Catalyst Pharmaceuticals's return on equity of 29.43%.

Xencor has a consensus price target of $28.20, signalling upside risk potential of 252.5%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.00 which suggests that it could grow by 36.22%. Given that Xencor has higher upside potential than Catalyst Pharmaceuticals, analysts believe Xencor is more attractive than Catalyst Pharmaceuticals.

Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.252%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $32.7M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.4M. Xencor's net income of -$48.4M is lower than Catalyst Pharmaceuticals's net income of $56.7M. Notably, Xencor's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 15.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.29x versus 5.87x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -147.92% compared to Xencor's net margin of --. Xencor's return on equity of -32.34% beat Plus Therapeutics's return on equity of --.

Xencor has a consensus price target of $28.20, signalling upside risk potential of 252.5%. On the other hand Plus Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 3327.44%. Given that Plus Therapeutics has higher upside potential than Xencor, analysts believe Plus Therapeutics is more attractive than Xencor.

Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.878, suggesting its less volatile than the S&P 500 by 12.185%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $32.7M, which are larger than Plus Therapeutics quarterly revenues of --. Xencor's net income of -$48.4M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Xencor's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.29x versus 0.35x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -147.92% compared to Xencor's net margin of -108.46%. Xencor's return on equity of -32.34% beat Ultragenyx Pharmaceutical's return on equity of -205.06%.

Xencor has a consensus price target of $28.20, signalling upside risk potential of 252.5%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $89.84 which suggests that it could grow by 164.01%. Given that Xencor has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Xencor is more attractive than Ultragenyx Pharmaceutical.

Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.284%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $32.7M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $139.3M. Xencor's net income of -$48.4M is higher than Ultragenyx Pharmaceutical's net income of -$151.1M. Notably, Xencor's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.29x versus 5.39x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -147.92% compared to Xencor's net margin of 26.7%. Xencor's return on equity of -32.34% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Xencor has a consensus price target of $28.20, signalling upside risk potential of 252.5%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $763.80 which suggests that it could grow by 55.79%. Given that Xencor has higher upside potential than Regeneron Pharmaceuticals, analysts believe Xencor is more attractive than Regeneron Pharmaceuticals.

Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.36% to investors and pays a quarterly dividend of $0.88 per share. Xencor pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Xencor quarterly revenues are $32.7M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Xencor's net income of -$48.4M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Xencor's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 12.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 4.29x versus 3.97x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.